Abstract:Abstract Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers with poor prognosis and high incidence. The clinical data analysis of liver hepatocellular carcinoma samples downloaded from The Cancer Genome Atlas reveals that the THO Complex 1 (THOC1) is remarkable upregulated in HCC and associated with poor prognosis. However, the underlying mechanism remains to be elucidated. We hypothesize that THOC1 can promote the proliferation of HCC. The present study aims to identify THOC1 as the target for HCC treatment and broaden our sights into therapeutic strategy for this disease. Methods Quantitative RT - PCR, Western blot, immunofluorescence and immunohistochemistry were used to measure gene and protein expression. Colony formation and cell cycle analysis were performed to evaluate the proliferation. The gene set enrichment analysis were performed to identify the function which THOC1 was involved in. The effects of THOC1 on the malignant phenotypes of hepatocellular cells were examined in vitro and in vivo. Results The gene set enrichment analysis reveals that THOC1 can promote the proliferation and G2/M cell cycle transition of HCC. Similarly, experimental results demonstrate that THOC1 promotes HCC cell proliferation and cell cycle progression. The knockdown of THOC1 leads to R-loop formation and DNA damage and confers sensitivity to cisplatin. In addition, in vivo data demonstrate that THOC1 can enhance tumorigenesis by increasing tumor cell proliferation. Furthermore, virtual screening predicts that THOC1 as a direct target of luteolin. Luteolin can induce DNA damage and suppress the proliferation of HCC by targeting THOC1. Furthermore, the inhibition of THOC1 activity by luteolin enhances the chemosensitivity of HCC tumor cells to cisplatin. Conclusions THOC1 was identified as a predictive biomarker vital for HCC-targeted treatments and improvement of clinical prognosis. Luteolin combined with cisplatin can effectively suppress HCC tumor growth, indicating a potential and effective therapeutic strategy that uses luteolin in combination with conventional cytotoxic agents for HCC treatment.

Hook1 Inhibits Malignancy and Epithelial–mesenchymal Transition in Hepatocellular Carcinoma

SHP2 Positively Regulates TGFβ1-induced Epithelial-Mesenchymal Transition Modulated by Its Novel Interacting Protein Hook1

The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.

Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma.

The Clinicopathological and Prognostic Implications of Tyrosine Phosphatase SHP2 and Ankyrin Hook1 Gene Expression in Non- Small Cell Lung Cancer Patients Treated with Gemcitabine Plus Platinum As First-Line Chemotherapy

HOOK3 suppresses proliferation and metastasis in gastric cancer via the SP1/VEGFA axis

Metallothionein 1H (MT1H) Functions As a Tumor Suppressor in Hepatocellular Carcinoma Through Regulating Wnt/β-catenin Signaling Pathway

Prognostic Significance of Hes-1, a Downstream Target of Notch Signaling in Hepatocellular Carcinoma.

Overexpression of SH2D1A Promotes Cancer Progression and is Associated with Immune Cell Infiltration in Hepatocellular Carcinoma Via Bioinformatics and in Vitro Study

Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma

E3 ubiquitin ligase CHIP interacts with transferrin receptor 1 for degradation and promotes cell proliferation through inhibiting ferroptosis in hepatocellular carcinoma

HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway

MicroRNA-337 Regulates the PI3K/AKT and Wnt/β-catenin Signaling Pathways to Inhibit Hepatocellular Carcinoma Progression by Targeting High-Mobility Group AT-hook 2.

Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin

FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production

Downregulation of Roundabout guidance receptor 2 suppresses hepatocellular carcinoma progression by interacting with Y-box binding protein 1

Circ_0084615 promotes epithelial‐mesenchymal transition‐mediated tumor progression in hepatocellular carcinoma

Overexpression of HnRNP A1 Promotes Tumor Invasion Through Regulating CD44v6 and Indicates Poor Prognosis for Hepatocellular Carcinoma

Mesoderm/mesenchyme homeobox l may promote tumor progression in human hepatocellular carcinoma

CircHECTD1 up-regulates mucin 1 expression to accelerate hepatocellular carcinoma development by targeting microRNA-485-5p via a competing endogenous RNA mechanism

Down-expression of homeobox A 9 promotes cancer cell invasion in human hepatocellular carcinomas